Board of Directors

Robert C. Bryce, Chairman of the Board

Robert C. Bryce, P. Eng., (ret’d), MBA is a graduate of the University of Toronto (B.Sc. Mining Engineering 1960) and of Western University (MBA 1964) with more than 50 years of practical and executive mining experience at all levels. From 1975 to 1990, he led the Selbaie Project from an advanced exploration project through feasibility to a 7,500 tpd producing mine. The Selbaie mine was Quebec’s largest base metal producer for a quarter century. From 1990 to 1994, Mr. Bryce was VP Mining for Aur Resources where he led the 280M$ development and start-up of the 4,000 tpd Louvicourt Cu-Zn-Ag-Au mine near Val-d’Or, Quebec. Mr. Bryce founded Xemac Resources in 1996 (now Vision Lithium) and presided over the Company until 2007. He has served as a director of several listed junior resource companies, including Integra Gold Corp., and a technical advisor to others. Mr. Bryce is a Fellow of the Canadian Institute of Mining and Metallurgy and served as President of the Quebec Mining Association in 1989-1990.

Pierre-Yves Desbiens, Chairman of the Audit Committee

Pierre-Yves Desbiens, MBA is currently COO and CFO of VuWall Technologies Inc., world leader in solutions for visualisation in the command-and-control room market. He has more than 35 years of professional and managerial experience, with the last 25 years as a COO and CFO for companies in the innovation field. Mr. Desbiens played a major role in the creation of successful start-ups, such as the NEOMED Institute and its subsidiary NÉOMED-Labs that subsequently became adMare Bioinnovations and Nexelis and ArthroLab Inc. Earlier in his career he was part of the leadership group that brought Oceanex to its successful IPO. Mr. Desbiens also served as portfolio manager at the Quebec Solidarity Funds and began his career with Deloitte, followed by PwC. He is an experienced director of a variety of public and private companies where he also serves as chair of the Audit Committee. Mr. Desbiens received his CPA, CA in 1989 and his MBA from the Université de Montréal (HEC) in 1997.

Dr. Michel Bazinet, Director and CEO

Dr. Michel Bazinet is Chief Executive Officer of Replicor Inc. since January 2003 and Chief Medical Officer since March 2015. He has been a Director of Replicor Inc. since June 2001. He is responsible for the development strategy of the Company, and, oversees all operations, including the planning of clinical trials. Previously, Dr. Bazinet worked as assistant professor in the departments of Urology and Oncology at McGill University in Montreal. He did his medical training at Sherbrooke University, his urology training at McGill University after which he did a 3-year fellowship in human tumor immunology and urologic oncology at the Memorial Sloan-Kettering Cancer Center in New York from 1984 to 1987. In 1996 Dr. Bazinet founded Mediconsult and was the Medical Director when it listed on NASDAQ in 1999. Dr. Bazinet has previously served as a member of the board of directors for 2 public companies and has been a consultant for many biotechnology projects. Dr. Bazinet is a listed inventor in over 200 patent applications.

Mr. John Bai, Director

John Bai has a MS in finance from the University of Tulsa, Oklahoma and a B.Sc. in Engineering from the Northwestern Polytechnic University - Xi'an, China. His previous achievements include Chief Project Manager for the Ministry of Aerospace, Beijing, China from 1989 to 2000 and Chief Financial Officer for China Infrastructure Construction from 2010 to 2011, which is based in Beijing, China. He is fluent in Chinese Mandarin and in English and has successfully passed the Canadian Securities Course. He has been an investment advisor for Global Capital Inc. and for Global Maxfin Capital Inc. both based in Toronto. He is currently a Managing director for Maple Financials Inc. and for a family fund. He is an investor in Replicor since 2012 and has helped Replicor raise over $6.5M by introducing investors to Replicor. He is very motivated to help Replicor succeed because he is personally affected by chronic Hepatitis B and he recognizes that our Company is bringing the best treatment to help achieve functional cure for this condition. He is a strong advocate for patients in the needs of our drug.